Latest News

Amgen and Boston Children's Hospital to identify new targets for pain syndromes

Amgen has entered a neuroscience research collaboration with Boston Children's Hospital to find new genes and drug targets for severe pain syndromes based on human genetic...

Amgen and Boston Children's Hospital to identify new targets for pain syndromes

Mutabilis joins European ENABLE project to develop new antibiotics

Mutabilis has been selected by the European Gram-negative antibacterial engine (ENABLE) project to focus on the improved development of antibiotics against infections caused by...

Mutabilis joins European ENABLE project to develop new antibiotics

Genomics and Biogen partner to discover new multiple sclerosis treatments

Genomics and Biogen partner to discover new multiple sclerosis treatments

US NIH launches $215m Partnership for Accelerating Cancer Therapies

US NIH launches $215m Partnership for Accelerating Cancer Therapies

Daiichi Sankyo, Astellas and Mitsubishi Tanabe partner to develop new therapeutics

Daiichi Sankyo, Astellas and Mitsubishi Tanabe partner to develop new therapeutics

NIH funds neonatal opioid withdrawal syndrome study

NIH funds neonatal opioid withdrawal syndrome study

Pfizer’s CTI and ADDF to co-fund new project to treat neurodegenerative diseases

The Alzheimer’s Drug Discovery Foundation (ADDF) and Pfizer’s Centers for Therapeutic Innovation (CTI) will jointly fund a new project that seeks to develop potential treatments for...

Pfizer’s CTI and ADDF to co-fund new project to treat neurodegenerative diseases

Transgene and Randox to develop oncolytic treatment for solid tumours

Transgene has a partnered with in-vitro diagnostics company Randox to combine their technologies and develop multifunctional oncolytic immunotherapies. ...

Transgene and Randox to develop oncolytic treatment for solid tumours

FDA grants breakthrough status to new Hodgkin's lymphoma therapy

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Adcetris (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of...

FDA grants breakthrough status to new Hodgkin's lymphoma therapy

Integra to sell neurosurgery assets to Natus Medical

Integra LifeSciences has signed an agreement to sell certain neurosurgery assets to Natus Medical in a deal valued at $47.5m....

Integra to sell neurosurgery assets to Natus Medical

Vanderbilt University and Bayer to evaluate new drug candidates for kidney diseases

Vanderbilt University Medical Center (VUMC) and Bayer are set to form a strategic research alliance to evaluate new drug candidates for the treatment of kidney...

Vanderbilt University and Bayer to evaluate new drug candidates for kidney diseases

Champions Oncology to collaborate with ALCMI to develop new cohort of PDX models

Champions Oncology has entered into a collaboration deal with the Addario Lung Cancer Medical Institute (ALCMI) to develop a new cohort of PDX models in patients with ROS1 gene rearrangement. ...

Champions Oncology to collaborate with ALCMI to develop new cohort of PDX models

US FDA accepts Pfizer’s sNDA for Xeljanz to treat ulcerative colitis

US FDA accepts Pfizer’s sNDA for Xeljanz to treat ulcerative colitis

Glenmark secures UK MHRA approval for anti-malarial medication

Glenmark Pharmaceuticals Europe (Glenmark) has secured final approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Maloff Protect, its range of atovaquone /...

Glenmark secures UK MHRA approval for anti-malarial medication

Synlogic completes first phase in ongoing R&D collaboration with AbbVie

US-based pharmaceutical firm Synlogic has met the first discovery milestone in its ongoing research and development (R&D) collaboration with...

Synlogic completes first phase in ongoing R&D collaboration with AbbVie

Roivant forms new subsidiary to develop urology therapies

Healthcare firm Roivant Sciences has formed a new subsidiary known as ‘Urovant Sciences’ to develop new therapies for addressing urologic...

Roivant forms new subsidiary to develop urology therapies

Lundbeck secures rights to IBC's research for Alzheimer's treatment

Lundbeck secures rights to IBC's research for Alzheimer's treatment

Novartis and IBM Watson to optimise cancer care and patient outcomes

Novartis and IBM Watson to optimise cancer care and patient outcomes

Merck and F-star to develop five bispecific immuno-oncology antibodies

German science and technology firm Merck has entered a new strategic collaboration with UK-based biopharmaceutical firm F-star to develop and commercialise five bispecific immuno-oncology...

Merck and F-star to develop five bispecific immuno-oncology antibodies

Innate Pharma acquires anti-C5aR antibody from Novo Nordisk

French biotechnology company Innate Pharma has signed an agreement to acquire a clinical-stage anti-C5a receptor (C5aR) antibody (IPH5401) from Danish pharmaceutical firm Novo Nordisk for...

Innate Pharma acquires anti-C5aR antibody from Novo Nordisk

UK CMA accuses Merck of breaking competition law with discount scheme

UK CMA accuses Merck of breaking competition law with discount scheme
cachename:Newscachekey:rd-137342983_-779801984_rd-1665407042_1857678299_rd-488908060_1460672566_ap1460672566_1857678299_541212976